Drugs / INO-4500
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04093076 | Jan 2021 → Oct 2022 | Lassa fever | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03805984 | May 2019 → Oct 2020 | Lassa fever | Inovio Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-17 | Inovio Pharmaceuticals | Results INOVIO Provides an Update on Lassa Fever and MERS Programs inovio.com ↗
Although INO-4500 and INO-4700 were well-tolerated by participants in our clinical trials and generated immune responses, the two-dose regimen did not meet CEPI's selection criteria for further development. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-17 | Inovio Pharmaceuticals | INOVIO Provides an Update on Lassa Fever and MERS Programs inovio.com ↗ |
| 2021-10-26 | Inovio Pharmaceuticals | INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa inovio.com ↗ |
| 2021-02-23 | Inovio Pharmaceuticals | INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa inovio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-4500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03805984 ↗ |
| Modality | Vaccine | “synthetic DNA-based vaccine” PMID 41208990 ↗ Oct 2025 |
| Route | Other | “intradermal (ID) injection” NCT03805984 ↗ |